Cardlytics (CDLX) Cost of Revenue (2017 - 2026)

Cardlytics has reported Cost of Revenue for 10 years, with the latest figure at $6.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 34.88% year-over-year to $6.8 million; the trailing twelve-month figure through Mar 2026 stood at $33.5 million (down 31.54% YoY), and the FY2025 full-year result was $39.5 million, down 25.02% from the prior year.
• Cost of Revenue for Q1 2026 stood at $6.8 million, down from $7.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $22.0 million in Q2 2022, with the low at $6.8 million in Q1 2026.
• Historically, Cost of Revenue has averaged $13.5 million across 5 years, with a median of $14.0 million in 2024.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 33.68% — and 2025, when it plunged 40.25%.
• Cardlytics' Cost of Revenue stood at $16.8 million in 2022, then fell by 16.13% to $14.1 million in 2023, then decreased by 19.62% to $11.3 million in 2024, then slumped by 33.67% to $7.5 million in 2025, then declined by 10.14% to $6.8 million in 2026.
• The last three Cost of Revenue figures came in at $6.8 million (Q1 2026), $7.5 million (Q4 2025), and $7.9 million (Q3 2025), per Business Quant data.